- Home
- ELBM vs ANVS Comparison
ELBM vs ANVS Comparison
Compare ELBM & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | ANVS |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.3M | 69.1M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ELBM | ANVS |
|---|---|---|
| Price | $0.58 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.15 | ★ $13.50 |
| AVG Volume (30 Days) | 860.3K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.54 |
| 52 Week High | $8.70 | $5.50 |
Technical Indicators
Market Signals| Indicator | ELBM | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 42.36 |
| Support Level | $0.54 | $1.73 |
| Resistance Level | $0.74 | $2.38 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.80 | 18.33 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry. The Company's operating segments are Refinery, Exploration and Evaluation, Corporate and Other.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.